Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Dow
Harvard Business School
Mallinckrodt
McKinsey

Last Updated: October 6, 2022

Patent: 10,106,546


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 10,106,546
Title:Immunoregulatory agents
Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
Inventor(s): Beck; Hilary Plake (Emerald Hills, CA), Jaen; Juan Carlos (Burlingame, CA), Osipov; Maksim (Belmont, CA), Powers; Jay Patrick (Pacifica, CA), Reilly; Maureen Kay (Belmont, CA), Shunatona; Hunter Paul (San Francisco, CA), Walker; James Ross (Menlo Park, CA), Zibinsky; Mikhail (Lodi, CA), Balog; James Aaron (Lambertville, NJ), Williams; David K. (Delran, NJ), Markwalder; Jay A. (Lahaska, PA), Cherney; Emily Charlotte (Newtown, PA), Shan; Weifang (Princeton, NJ), Huang; Audris (New Hope, PA)
Assignee: Flexus Biosciences, Inc. (Princeton, NJ)
Application Number:15/469,707
Patent Claims:see list of patent claims

Details for Patent 10,106,546

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bristol-myers Squibb Company YERVOY ipilimumab Injection 125377 03/25/2011 See Plans and Pricing 2034-11-05
Merck Sharp & Dohme Corp. KEYTRUDA pembrolizumab For Injection 125514 09/04/2014 See Plans and Pricing 2034-11-05
Merck Sharp & Dohme Corp. KEYTRUDA pembrolizumab Injection 125514 01/15/2015 See Plans and Pricing 2034-11-05
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 12/22/2014 See Plans and Pricing 2034-11-05
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 10/04/2017 See Plans and Pricing 2034-11-05
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 08/27/2021 See Plans and Pricing 2034-11-05
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Colorcon
Medtronic
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.